XML 36 R23.htm IDEA: XBRL DOCUMENT
v3.20.4

Equity Compensation | 12 Months Ended
--- | ---
Dec. 31, 2020
Share-based Payment Arrangement [Abstract] |
Equity Compensation | EQUITY COMPENSATION The Company has equity compensation plans that authorize the issuance of restricted stock units or options for shares of Common Stock to directors, officers and key employees. Equity-based compensation is designed to reward long-term contributions to the Company and provide incentives for recipients to join and to remain with the Company. The exercise price of stock options, determined by a committee of the Board of Directors, may not be less than the fair market value of the Common Stock on the grant date. Options become exercisable over periods not exceeding ten years. The Company’s practice has been to issue new shares upon the exercise of the options. The Company established Incentive Stock Option Plans for the purpose of attracting and retaining executive officers and key employees, and to align management’s interest with those of the shareholders. Generally, the options must be exercised within 10 years from the grant date and vest ratably over a five-year period. The exercise price for the options is equal to the share price at the date of grant. At December 31, 2020, the Company had options outstanding for 485,027 shares under the plans. The Company established the Directors Stock Option Plans for the purpose of attracting and retaining the services of experienced and knowledgeable outside directors, and to align their interest with those of the shareholders. The options must be exercised within ten years from the grant date. The exercise price for the option is equal to the share price at the date of grant and vests six months from the grant date. At December 31, 2020, the Company had options outstanding for 92,115 shares under the plans. During 2017, the Company established the Long Term Incentive Plan for the purpose of attracting and retaining directors, executive officers and key employees, and to align management's interest with those of the shareholders. The Plan contemplates the use of a mix of equity award types, and contains, with certain exceptions, a three-year pro-rata vesting schedule for time-based awards. The Long Term Incentive Plan was amended on December 14, 2018 to provide a six-month pro-rata vesting schedule for directors. For stock options, the exercise price is equal to the share price on the date of grant. Upon inception, the remaining options available for future grant under the 2011 Incentive Stock Option Plan and the Directors Stock Option Plans were rolled in the Long Term Incentive Plan, and no further grants may be made out of those plans. At December 31, 2020, the Company had stock options and RSU's outstanding of 557,238 shares under the Long Term Incentive Plan, and there were 1,123,291 shares available for future grant under this plan. Stock compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Vesting requirements vary for directors, officers and key employees. In general, options granted to outside directors vest six months from the date of grant and options granted to officers and key employees straight line vest over a five-year period from the date of grant. RSUs granted to officers and key employees cliff vest three years from the date of grant. The following table provides compensation expense information based on the fair value of stock options and RSU's for the years ended December 31 as follows:
(In thousands) | 2020 |  | 2019 |  | 2018
Equity-based Compensation Expense | $ | 5,184 |  |  | $ | 3,843 |  |  | $ | 3,098 |
Tax Benefit | (709) |  |  | (452) |  |  | (179) |
Equity-based Compensation Expense, Net of Tax | $ | 4,475 |  |  | $ | 3,391 |  |  | $ | 2,919 |
Stock Options No options were granted during the year ending December 31, 2020.
| 2020 |  | 2019 |  | 2018
Weighted Average Fair Value of the Options Granted | $ | — |  |  | $ | 11.93 |  |  | $ | 14.64 |
The weighted average fair value for these options was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:
| 2020 |  | 2019 |  | 2018
Risk-free Interest Rate | — |  | 1.67% – 1.78% |  | 2.63% – 2.87%
Dividend Yield | —% |  | —% |  | —%
Volatility Factor | — |  | 0.39 |  | 0.39
Expected Life in Years | — |  | 5.0 – 7.0 |  | 5.0 – 8.0 years
To determine expected volatility, the Company uses historical volatility based on weekly closing prices of its Common Stock and considers currently available information to determine if future volatility is expected to differ over the expected terms of the options granted. The risk-free rate is based on the U.S. Treasury yield curve at the time of grant for the appropriate term of the options granted. Expected dividends are based on the Company’s history and expectation of dividend payouts. The expected term of stock options is based on vesting schedules, expected exercise patterns and contractual terms. A summary of the Company’s stock option activity and related information for the years ended December 31 is as follows:
| 2020
(Aggregate intrinsic value in thousands) | Options |  | Weighted Average Exercise Price |  | Aggregate Intrinsic Value
Outstanding at January 1 | 1,116,045 |  |  | $ | 23.07 |  |  | $ | — |
Options Granted | — |  |  | $ | — |  |  |
Options Exercised | (169,763) |  |  | $ | 7.88 |  |  |
Options Forfeited | (33,359) |  |  | $ | 34.05 |  |  |
Outstanding at December 31 | 912,923 |  |  | $ | 25.50 |  |  | $ | — |
Exercisable at December 31 | 697,501 |  |  | $ | 23.64 |  |  | $ | — |
The aggregate intrinsic value in the preceding table represents the total pretax option holder’s intrinsic value, based on the Company’s closing stock price of Common Stock which would have been received by the option holders had all option holders exercised their options as of that date. The Company’s closing stock price of Common Stock was $13.23, $27.95 and $30.45 as of December 31, 2020, 2019 and 2018, respectively. The weighted average fair value of options vested during 2020, 2019 and 2018 was $14.77, $15.91 and $16.54, respectively. The total fair value of options that vested during the year amounted to $1.4 million, $1.6 million and $1.4 million for the years ended December 31, 2020, 2019 and 2018, respectively. At December 31, 2020, total compensation costs related to non-vested option awards not yet recognized amounts to $4.3 million and will be recognized over a weighted average period of approximately 2 years. The following is a summary of weighted average exercise prices and contractual lives for outstanding and exercisable stock options as of December 31, 2020:
| Outstanding |  | Exercisable
Exercise Price Range | Shares |  | Weighted Average Remaining Life in Years |  | Weighted Average Exercise Price |  | Shares |  | Weighted Average Remaining Life in Years |  | Weighted Average Exercise Price
$3.19 – $13.63 | 255,500 |  |  | 1.5 |  | $ | 10.98 |  |  | 255,500 |  |  | 1.5 |  | $ | 10.98 |
$22.69 – $35.82 | 648,296 |  |  | 6.4 |  | $ | 30.93 |  |  | 432,874 |  |  | 5.5 |  | $ | 30.65 |
$45.89 – $45.89 | 9,127 |  |  | 4.2 |  | $ | 45.89 |  |  | 9,127 |  |  | 4.2 |  | $ | 45.89 |
| 912,923 |  |  | 5.0 |  | $ | 25.50 |  |  | 697,501 |  |  | 4.0 |  | $ | 23.64 |
Restricted Stock Units The fair value of each RSU granted is equal to the fair market value of the Company’s Common Stock on the date of grant. The RSU’s granted to employees cliff vest three years from the date of grant, while RSU’s granted to directors cliff vest six months from the date of grant. There were 190,100 RSU’s granted in 2020 at a weighted-average price of $19.69, of which 44,800 awards were vested during 2020. Forfeitures during the year were insignificant. Included in total equity-based compensation expense for the year ended December 31, 2020 was $2.6 million related to RSU's. At December 31, 2020, total compensation costs related to non-vested awards not yet recognized amounts to $2.7 million and will be recognized over a weighted average period of approximately 1.5 years. Employee Stock Purchase Plan In addition to the stock options and RSU's discussed above, the Company has established the Employee Stock Purchase Plan to encourage employees to invest in Astronics Corporation. The plan provides employees the opportunity to invest up to the IRS annual maximum of approximately $25,000 in Astronics common stock at a price equal to 85% of the fair market value of the Astronics common stock, determined each October 1. Employees are allowed to enroll annually. Employees indicate the number of shares they wish to obtain through the program and their intention to pay for the shares through payroll deductions over the annual cycle of October 1 through September 30. Employees can withdraw anytime during the annual cycle, and all money withheld from the employees pay is returned with interest. If an employee remains enrolled in the program, enough money will have been withheld from the employees’ pay during the year to pay for all the shares that the employee opted for under the program. At December 31, 2020, employees had subscribed to purchase 533,138 shares at $6.73 per share. The weighted average fair value of the options was approximately $3.43, $8.26 and $8.48 for options granted during the year ended December 31, 2020, 2019 and 2018, respectively. The fair value for the options granted under the Employee Stock Purchase Plan was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:
| 2020 |  | 2019 |  | 2018
Risk-free Interest Rate | 0.12 | % |  |  | 1.73 | % |  |  | 2.60 | % |
Dividend Yield | — | % |  |  | — | % |  |  | — | % |
Volatility Factor | 1.00 |  |  | 0.53 |  |  | 0.33 |
Expected Life in Years | 1.0 |  |  | 1.0 |  |  | 1.0 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration